[go: up one dir, main page]

MX9706450A - Vacuna para hepatitis b. - Google Patents

Vacuna para hepatitis b.

Info

Publication number
MX9706450A
MX9706450A MX9706450A MX9706450A MX9706450A MX 9706450 A MX9706450 A MX 9706450A MX 9706450 A MX9706450 A MX 9706450A MX 9706450 A MX9706450 A MX 9706450A MX 9706450 A MX9706450 A MX 9706450A
Authority
MX
Mexico
Prior art keywords
hepatitis
vaccine
compromising
combination
component
Prior art date
Application number
MX9706450A
Other languages
English (en)
Inventor
Pierre Hauser
Nathalie Marie Josephe C Garco
N
Pierre Desmons
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10770292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9706450(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of MX9706450A publication Critical patent/MX9706450A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se provee una formulacion novedosa de vacuna, que comprende un componente de hepatitis B, particularmente un antígeno de superficie de hepatitis B, en combinacion con fosfato de aluminio y un lípido A de monofosforilo 3-O-desacilado.
MX9706450A 1995-02-25 1997-08-22 Vacuna para hepatitis b. MX9706450A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9503863.4A GB9503863D0 (en) 1995-02-25 1995-02-25 Vaccine compositions

Publications (1)

Publication Number Publication Date
MX9706450A true MX9706450A (es) 1998-07-31

Family

ID=10770292

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9706450A MX9706450A (es) 1995-02-25 1997-08-22 Vacuna para hepatitis b.

Country Status (36)

Country Link
US (1) US5972346A (es)
EP (1) EP0810877B1 (es)
JP (1) JP3881015B2 (es)
KR (1) KR100365373B1 (es)
CN (1) CN1101225C (es)
AP (1) AP766A (es)
AR (1) AR002279A1 (es)
AT (1) ATE209045T1 (es)
AU (1) AU695921B2 (es)
BG (1) BG101851A (es)
BR (1) BR9607458A (es)
CA (1) CA2212552C (es)
CZ (1) CZ288417B6 (es)
DE (1) DE69617211T2 (es)
DK (1) DK0810877T3 (es)
EA (1) EA199700126A1 (es)
ES (1) ES2166879T3 (es)
FI (1) FI118118B (es)
GB (1) GB9503863D0 (es)
HK (1) HK1004117A1 (es)
HU (1) HU224832B1 (es)
IL (1) IL117249A (es)
MA (1) MA23814A1 (es)
MX (1) MX9706450A (es)
MY (1) MY113428A (es)
NO (1) NO319394B1 (es)
NZ (1) NZ302674A (es)
OA (1) OA10612A (es)
PL (1) PL182679B1 (es)
PT (1) PT810877E (es)
SA (1) SA96160633B1 (es)
SK (1) SK115097A3 (es)
TR (1) TR199700849T1 (es)
TW (1) TW467745B (es)
WO (1) WO1996026741A1 (es)
ZA (1) ZA961460B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620414B2 (en) * 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
ES2272069T3 (es) 1998-05-22 2007-04-16 Ottawa Health Research Institute Metodos y productos para inducir inmunidad en mucosas.
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
EP1126876B1 (en) * 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
EP1140155A4 (en) * 1998-12-23 2004-11-03 Merck & Co Inc IMPROVED RECOMBINATION HEPATITIS B ENVELOPE ANTIGEN
EP2322210A1 (en) 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
AU2006215419B2 (en) * 2005-02-16 2012-03-08 Novartis Vaccines And Diagnostics, Inc. Adjuvant composition comprising aluminium phosphate and 3D-MPL
AP2745A (en) * 2005-08-02 2013-09-30 Novartis Vaccines & Diagnostic Reducing interference between oil-containing adjuvants and surfactant-containing antigens
NZ592713A (en) 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
PT1951299E (pt) 2005-11-04 2012-02-28 Novartis Vaccines & Diagnostic Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores
EP2368572B1 (en) 2005-11-04 2020-03-04 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN100415294C (zh) * 2005-12-23 2008-09-03 中国农业大学 一种治疗和/或预防乙肝的药物
KR20110110853A (ko) 2006-01-27 2011-10-07 노파르티스 파르마 아게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
EP1862176A1 (de) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
EP1862177A1 (de) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Ein Verfahren zur Herstellung einer Impfzusammensetzung
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
AU2007297178B2 (en) 2006-09-11 2014-07-24 Novartis Ag Making influenza virus vaccines without using eggs
CA2671629C (en) 2006-12-06 2017-08-15 Novartis Ag Vaccines including antigen from four strains of influenza virus
AU2008269439B2 (en) 2007-06-27 2013-12-19 Novartis Ag Low-additive influenza vaccines
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
AR077757A1 (es) 2009-07-15 2011-09-21 Novartis Ag Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
HUE034673T2 (en) 2011-05-13 2018-02-28 Glaxosmithkline Biologicals Sa Pre-fusion rsv f antigens
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
US12128100B2 (en) 2018-11-13 2024-10-29 Variation Biotechnologies Inc. Immunogenic compositions for treatment of Hepatitis B

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69031556T2 (de) * 1989-07-25 1998-05-14 Smithkline Beecham Biologicals S.A., Rixensart Antigene sowie Verfahren zu deren Herstellung
JP3307392B2 (ja) * 1991-05-29 2002-07-24 オリジン・メドシステムズ・インク 内視鏡による手術用の器官後退装置
MY111880A (en) * 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
ES2118963T3 (es) * 1992-05-23 1998-10-01 Smithkline Beecham Biolog Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
ATE204762T1 (de) * 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
GB9311536D0 (en) * 1993-06-04 1993-07-21 Unilever Plc Hot soluble low density extractable food product

Also Published As

Publication number Publication date
HUP9801242A1 (hu) 1998-08-28
IL117249A (en) 2000-11-21
KR100365373B1 (ko) 2003-07-07
JP3881015B2 (ja) 2007-02-14
AP9701060A0 (en) 1997-10-31
KR19980702480A (ko) 1998-07-15
PL182679B1 (pl) 2002-02-28
DK0810877T3 (da) 2002-02-25
CN1176604A (zh) 1998-03-18
EP0810877B1 (en) 2001-11-21
AR002279A1 (es) 1998-03-11
EA199700126A1 (ru) 1998-02-26
IL117249A0 (en) 1996-06-18
WO1996026741A1 (en) 1996-09-06
BR9607458A (pt) 1998-06-30
DE69617211T2 (de) 2002-07-25
MA23814A1 (fr) 1996-10-01
AP766A (en) 1999-09-17
PT810877E (pt) 2002-04-29
NO319394B1 (no) 2005-08-08
OA10612A (en) 2002-08-29
HUP9801242A3 (en) 2000-08-28
SA96160633B1 (ar) 2005-10-15
BG101851A (en) 1998-04-30
EP0810877A1 (en) 1997-12-10
GB9503863D0 (en) 1995-04-19
FI973457A0 (fi) 1997-08-22
DE69617211D1 (en) 2002-01-03
AU695921B2 (en) 1998-08-27
TR199700849T1 (xx) 1998-01-21
NO973873D0 (no) 1997-08-22
HK1004117A1 (en) 1998-11-20
CZ267497A3 (cs) 1998-02-18
HU224832B1 (en) 2006-03-28
MY113428A (en) 2002-02-28
ZA961460B (en) 1996-08-29
AU4878096A (en) 1996-09-18
PL321966A1 (en) 1998-01-05
NO973873L (no) 1997-08-22
FI973457A (fi) 1997-08-22
ATE209045T1 (de) 2001-12-15
FI118118B (fi) 2007-07-13
US5972346A (en) 1999-10-26
ES2166879T3 (es) 2002-05-01
CN1101225C (zh) 2003-02-12
SK115097A3 (en) 1998-02-04
NZ302674A (en) 1999-01-28
CZ288417B6 (en) 2001-06-13
CA2212552C (en) 2006-07-11
CA2212552A1 (en) 1996-09-06
TW467745B (en) 2001-12-11
JPH11501018A (ja) 1999-01-26

Similar Documents

Publication Publication Date Title
MX9706450A (es) Vacuna para hepatitis b.
AU9052091A (en) Vaccines based on hepatitis b surface antigen
AU709406C (en) Combined vaccines comprising hepatitis B surface antigen and other antigens
MY111880A (en) Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
AU6304996A (en) Vaccines against hepatitis c
AU6803298A (en) Vaccines
AU7322291A (en) Abutment for dental appliances and the like
MY110086A (en) Herpes simplex virus vaccines comrpising glycoprotein d and 3d-mpl
AU1093088A (en) Hepatitis b virus surface antigens and hybrid antigens containing them
AU7789194A (en) Improvements in and relating to vaccines
AU4278696A (en) Yeast telomerase components and methods using them
WO1999056772A3 (en) Hepatitis vaccine
AU8544591A (en) Antigens associated with polymyositis and with dermatomyositis
USD359530S (en) Alligator figure
CA2238099A1 (en) Dental instrument with improved grip
AU2968892A (en) Vaccines based on modified type 1 bovine herpesviruses
USD359531S (en) Alligator figure
USD359533S (en) Bear figure
HU9403117D0 (en) 17alpha and 17beta-substituted estra-1,3,5(10)-triene-3-carboxylic acids
AU3931197A (en) Vaccines and antigenic conjugates
AUPM625794A0 (en) The Bravura luminescent and flourescent special effects techniques
GB9522485D0 (en) Hepatitis b surface antigen variants
AU109110B2 (en) Improvements in friction clutches
AU4240489A (en) Pyruvate oxidase mutants and process for the preparation thereof
AU108319S (en) An outdoor advertising chair attachments